Skip to main content

Table 4 Multilevel analysis of plasma AD biomarkers

From: Feasibility and preliminary effects of exercise interventions on plasma biomarkers of Alzheimer’s disease in the FIT-AD trial: a randomized pilot study in older adults with Alzheimer’s dementia

 

Plasma Ab42/40 ratio

t-tau

p-tau181

Coef.

95% CI

Coef.

95% CI

Coef.

95% CI

Fixed effects

 Timea

  3 months

0.002

[–0.001; 0.005]

–0.007

[–0.144; 0.131]

0.086

[–0.545; 0.718]

  6 months

0.001

[–0.002; 0.004]

–0.020

[–0.158; 0.117]

0.627

[–0.005; 1.259]

 Groupb

  Cycling

0.003

[–0.005; 0.012]

0.019

[–0.160; 0.199]

0.322

[–0.795; 1.439]

 Time×Group

  3 months×Cycling

–0.003

[–0.006; 0.001]

0.032

[–0.137; 0.201]

0.218

[–0.561; 0.996]

  6 months×Cycling

–0.002

[–0.006; 0.001]

–0.040

[–0.206; 0.127]

–0.210

[–0.988; 0.567]

 APOE genotypec

  ε2/ε3

–0.007

[–0.028; 0.013]

0.179

[–0.209; 0.567]

1.827

[–0.794; 4.448]

  ε2/ε4

–0.007

[–0.018; 0.003]

0.234

[–0.425; –0.043]

–0.811

[–2.079; 0.457]

  ε4/ε4

–0.002

[–0.012; 0.008]

–0.046

[–0.239; 0.147]

–0.228

[–1.516; 1.060]

 Age

0.000

[–0.000; 0.001]

0.007

[–0.003; 0.018]

0.069

[0.001; 0.138]

 Femaled

–0.006

[–0.014; 0.002]

–0.041

[–0.191; 0.110]

–0.849

[–1.846; 0.149]

 Whitee

0.002

[–0.011; 0.015]

0.010

[–0.235; 0.255]

–1.617

[–3.242; 0.008]

 Education in years

0.001

[–0.000; 0.002]

–0.019

[–0.043; 0.005]

–0.062

[–0.220; 0.097]

 Marriedf

–0.006

[–0.017; 0.005]

0.262

[0.054; 0.470]

1.356

[–0.024; 2.737]

 MMSE

0.000

[–0.002; 0.001]

–0.009

[–0.033; 0.016]

0.062

[–0.099; 0.224]

 Constant

0.060

[0.045; 0.075]

0.685

[0.391; 0.978]

3.241

[1.336; 5.147]

Variance components

 Level 1: within-person

0.000

[0.000; 0.000]

0.018

[0.008; 0.040]

0.948

[0.501; 1.793]

 Level 2: Initial status

0.000

[0.000; 0.000]

0.020

[0.013; 0.029]

0.377

[0.247; 0.576]

Deviance

286.07

23.81

–90.38

AIC

–538.14

–13.62

214.75

BIC

–498.97

25.55

252.73

N

74g

74g

69h

  1. The reference groups are (a) baseline; (b) stretching group; (c) ε3/ε4; (d) male; (e) non-White; and (f) not married; bold if significant at the .05 level of significance; (g) the sample sizes for the stretching and the cycling groups are 8 and 18, 8 and 15, and 8 and 17 at baseline, and 3 and 6 months, respectively; (h) the sample sizes for the stretching and the cycling groups are 7 and 15, 8 and 15, and 8 and 16 at baseline, and 3 and 6 months, respectively